Examples of Quotient Suisse in a sentence
Ortho Arbitration and Settlement The Company’s subsidiaries, Quotient Suisse and QBD (QS-IP) Limited were party to the Prior Ortho Agreement with Ortho related to the commercialization and distribution of certain MosaiQ products.
Having concluded that the criteria for revocation of the Authorizations under section 564(g)(2)(C) of the FD&C Act are met, FDA has revoked the EUA of Bio- Rad Laboratories for the BioPlex 2200 SARS–CoV–2 IgG and of Quotient Suisse SA for the MosaiQ COVID–19 Antibody Magazine.
This extends to classes of models in the obvious way, which allows us to compare ModP(SP ) and ModM(SP ).Proposition 8.5 For any specification SP in IP, |ModM(SP )|⊆ Mod P(SP ).Proof: By easy induction on the structure of SP.
Ortho Arbitration The Company’s subsidiaries, Quotient Suisse and QBD (QS-IP) Limited were party to a distribution and supply agreement with Ortho related to the commercialization and distribution of certain MosaiQ products (the “Ortho Agreement”).
Our subsidiaries, Quotient Suisse and QBD (QS-IP) Limited were party to a distribution and supply agreement with Ortho-Clinical Diagnostics, Inc., or “Ortho”, related to the commercialization and distribution of certain MosaiQ products, which we refer to as the Ortho Agreement.
Because Bio-Rad Laboratories notified FDA that Bio-Rad Laboratories has not commercialized the authorized product in the United States and requested FDA revoke the BioPlex 2200 SARS–CoV–2 IgG, FDA hasdetermined that it is appropriate to protect the public health or safety to revoke this Authorization.In a request received by FDA on December 22, 2021, Quotient Suisse SA requested termination of, and on January 11, 2022, FDA revoked, the Authorization for the MosaiQ COVID– 19 Antibody Magazine.
On September 25, 2020, FDA issued an EUA to Quotient Suisse SA for the MosaiQ COVID–19 Antibody Magazine, subject to the terms of the Authorization.
A summary of benefits is available in the Quotient Suisse SA Benefits Brochure and further detailed in the official plans rules which may be amended from time to time.
Such limitation will not release Quotient Suisse SA from its obligations in excess of the Swiss Available Amount, but will merely postpone the performance date thereof until such time(s) when such performance is again permitted from a Swiss legal and Swiss accounting point of view.
Borrower shall use the proceeds of the Credit Extensions solely for (a) transaction fees and other expenses incurred in connection with the Financing Documents, (b) subject the limitations set forth in Section 7.7 hereof with respect to Quotient Suisse, for working capital needs of Borrower and its Subsidiaries and the other Credit Parties, and (c) any other Permitted Purpose specified in the Credit Facility Schedule for such Credit Facility.